This study is not accepting new patients

Treatment of Dravet Syndrome With Fenfluramine (Expanded Access Protocol)

a study on Dravet Syndrome Epilepsy

Summary

Eligibility
for people ages 2 years and up (full criteria)
Location
at Los Angeles, California
Dates
study started
Principal Investigator
by Shaun Hussain, MD

Description

Summary

The purpose of this research study is to (1) provide access to fenfluramine for patients with intractable epilepsy associated with Dravet syndrome, and (2) evaluate the safety of fenfluramine.

Details

The purpose of this research study is to (1) provide access to fenfluramine for patients with intractable epilepsy associated with Dravet syndrome, and (2) evaluate the safety of fenfluramine.

Keywords

Dravet Syndrome, Myoclonic Epilepsies, Syndrome, Fenfluramine

Eligibility

For people ages 2 years and up

Inclusion Criteria:

  • Genetic diagnosis of Dravet syndrome with intractable seizures despite failing all available medications for seizures.

Location

  • University of California, Los Angeles not accepting new patients
    Los Angeles California 90095-1752 United States

Lead Scientist at UCLA

  • Shaun Hussain, MD
    Hs Clinical Professor, Pediatrics, Medicine. Authored (or co-authored) 45 research publications

Details

Status
not accepting new patients
Start Date
Sponsor
University of California, Los Angeles
ID
NCT04437004
Study Type
Expanded Access
Last Updated